Emalex
Emalex Biosciences
Chicago, United States · Founded 2018 · $285.0M raised
- Headquarters
- Chicago, Illinois
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- emalexbiosciences.com
- Total Funding
- $285.0M
- Last Round
- $250.0M Series DNov 2022
- Rounds
- 4
About
Emalex Biosciences is a Chicago-based clinical-stage biopharmaceutical company created by Paragon Biosciences in 2018. The company develops novel treatments for central nervous system disorders, with its lead asset ecopipam — a first-in-class selective dopamine D1 receptor antagonist — in late-stage development for pediatric Tourette syndrome. In April 2026, Teva announced its acquisition of Emalex for $700 million.
Summary
Emalex is a Biotech company based in Chicago, United States, founded in 2018. It has raised $285.0M in total across 4 rounds, most recently a $250.0M Series D round in Nov 2022. Investors include Paragon Biosciences, Bain Capital Life Sciences and Valor Equity Partners.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2022
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...